Search results for "Risk"

showing 10 items of 9963 documents

Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involvin…

2013

The available studies have reported the benefits of statins on all-cause and cardiovascular mortality in chronic kidney disease (CKD) patients. However studies in end-stage renal disease patients on dialysis yielded conflicting results. Therefore, we performed a meta-analysis and provide the most reliable trial data to date on the impact of statin therapy on cardiovascular events and death from all causes in CKD patients. Data from PubMed, Web of Science, Cochrane Library, and Scopus for the years 1966 to October 2012 were searched. The final meta-analysis included 11 randomized controlled trials involving 21,295 participants with CKD. Among them 6857 were on dialysis. The use of statins in…

medicine.medical_specialtymedicine.medical_treatmentDiseaseCochrane Librarylaw.inventionRandomized controlled triallawRenal DialysisInternal medicinemedicineHumansRenal Insufficiency ChronicIntensive care medicineDialysisRandomized Controlled Trials as TopicPharmacologybusiness.industrymedicine.diseaseConfidence intervalCardiovascular events Chronic kidney disease Dialysis Mortality Statins StrokeStrokeCardiovascular DiseasesMeta-analysisRelative riskHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessKidney diseasePharmacological research
researchProduct

Amyloidosis in Inflammatory Bowel Disease: A Systematic Review of Epidemiology, Clinical Features, and Treatment.

2015

Background and Aims: Amyloidosis is a rare complication of inflammatory bowel disease [IBD]; its low prevalence has hindered both descriptive and therapeutic studies. The aim of this study was to estimate the prevalence of amyloidosis in IBD and the risk factors associated with this complication. Methods: This paper presents an observational study, followed by a systematic review of the epidemiological and clinical characteristics of the disease and a review of the diagnostic and therapeutic options. Results: The prevalence of amyloidosis among IBD patients is 0.53% (95% confidence interval [CI]: 0.32–0.75), although epidemiological data suggest that it may be under-diagnosed. The phenotype…

medicine.medical_specialtymedicine.medical_treatmentDiseaseInflammatory bowel disease03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineEpidemiologymedicinePrevalenceHumansProteinuriabusiness.industryAmyloidosisGastroenterologyImmunosuppressionGeneral MedicineAmyloidosismedicine.diseaseInflammatory Bowel DiseasesSurgeryPhenotypeTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyObservational studymedicine.symptomComplicationbusinessJournal of Crohn'scolitis
researchProduct

Tobacco smoking and risk of endometriosis: a systematic review and meta-analysis

2014

Objective Since conflicting results have been published on the role of tobacco smoking on the risk of endometriosis, we provide an up-to-date summary quantification of this potential association. Design We performed a PubMed/MEDLINE search of the relevant publications up to September 2014, considering studies on humans published in English. We searched the reference list of the identified papers to find other relevant publications. Case–control as well as cohort studies have been included reporting risk estimates on the association between tobacco smoking and endometriosis. 38 of the 1758 screened papers met the inclusion criteria. The selected studies included a total of 13 129 women diagn…

medicine.medical_specialtymedicine.medical_treatmentEndometriosisMEDLINEEndometriosisGlobal HealthRisk FactorsInternal medicineEpidemiologyObstetrics and Gynaecologymedicine1845EPIDEMIOLOGYHumans1506Gynecologybusiness.industry1731Risk FactorResearchSmokingGeneral MedicineGYNAECOLOGYFormer Smokermedicine.diseaseSettore MED/40 - Ginecologia E Ostetricia1692Relative riskMeta-analysisSmoking cessation1734FemaleSmoking CessationMorbiditybusinessCohort studyHumanBMJ Open
researchProduct

What have we learnt 50 years after the first Fontan procedure?

2020

The Fontan procedure is often the only definitive palliative surgical option for patients with a variety of complex CHD sharing in common, a single, dominant ventricle. In recent decades, imaging and therapeutic improvement have played a crucial role in those patients in whom many complications can hamper their life. After 50 years from the first procedure, heart transplantation remains the only definitive treatment for those with a failing Fontan circulation.

medicine.medical_specialtymedicine.medical_treatmentHeart VentriclesMEDLINEFontan ProcedureHistory 21st CenturyUniventricular HeartFontan circulationFontan procedureRisk FactorsMedicineHumansVentricular FunctionTreatment Failurecardiovascular diseasesIntensive care medicineHeart transplantationbusiness.industryHemodynamicsGeneral MedicineRecovery of FunctionHistory 20th CenturyHeart TransplantationDiffusion of InnovationCardiology and Cardiovascular MedicinebusinessFontan total cavopulmonary connection univentricular heart
researchProduct

Hepatitis C virus infection in hemodialyzed patients.

2007

In spite of our present improved knowledge of the epidemiology and pathways of contamination of the hepatitis C virus (HCV), infection still remains a public health problem. One category of patients who have suffered greatly from the consequences of HCV infection is certainly that of hemodialysis patients. In the past, in fact, their need for transfusions exposed these patients to infection and, as a result, subjects on dialysis for over 15 years are today paying the price for those inevitable transfusions, as the virus and its pathways of contagion were unknown then. However, still today, albeit at a much lower prevalence, even subjects with a shorter dialysis age present a higher prevalen…

medicine.medical_specialtymedicine.medical_treatmentHepatitis C virusPopulationBiomedical EngineeringMedicine (miscellaneous)Bioengineering030204 cardiovascular system & hematologymedicine.disease_causeAsymptomaticAntiviral AgentsBiomaterials03 medical and health scienceschemistry.chemical_compoundLiver disease0302 clinical medicineRenal DialysisRisk FactorsInternal medicinemedicineHumanseducationDialysiseducation.field_of_studybusiness.industryRibavirinMortality rateTransfusion ReactionGeneral Medicinemedicine.diseaseHepatitis Cchemistry030220 oncology & carcinogenesisImmunologyHemodialysismedicine.symptombusinessThe International journal of artificial organs
researchProduct

The diagnosis of and treatment recommendations for anxiety disorders.

2014

Anxiety disorders (panic disorder/agoraphobia, generalized anxiety disorder, social phobia, and specific phobias) are the most common mental illnesses. For example, the 12-month prevalence of panic disorder/agoraphobia is 6%.This guideline is based on controlled trials of psychotherapy and pharmacotherapy, retrieved by a systematic search for original articles that were published up to 1 July 2013. Experts from 20 specialty societies and other organizations evaluated the evidence for each treatment option from all available randomized clinical trials and from a synthesis of the recommendations of already existing international and German guidelines.403 randomized controlled trials were eval…

medicine.medical_specialtymedicine.medical_treatmentMEDLINElaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled triallawRisk FactorsmedicineHumansIntensive care medicinePsychiatryPsychodynamic psychotherapyPsychotropic Drugsbusiness.industryGeneral MedicineGuidelineClinical Practice GuidelineAnxiety Disorders030227 psychiatry3. Good healthCognitive behavioral therapyPsychotherapyNeurologyPractice Guidelines as TopicAnxietymedicine.symptomReuptake inhibitorbusiness030217 neurology & neurosurgeryDeutsches Arzteblatt international
researchProduct

Multicenter and all-comers validation of a score to select patients for manual thrombectomy, the DDTA score.

2021

Background Routine manual thrombectomy (MT) is not recommended in primary percutaneous coronary intervention (P-PCI) but it is performed in many procedures. The objective of our study was validating the DDTA score, designed for selecting patients who benefit most from MT. Methods Observational and multicenter study of all consecutive patients undergoing P-PCI in five institutions. Results were compared with the design cohort and the performance of the DDTA was analyzed in all patients. Primary end-point of the analyses was TIMI 3 after MT; secondary endpoints were final TIMI 3, no-reflow incidence, in-hospital mortality and in-hospital major cardiovascular events (MACE). In-hospital prognos…

medicine.medical_specialtymedicine.medical_treatmentMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingIn patient030212 general & internal medicinecardiovascular diseasesEdetic AcidThrombectomyPrimary angioplastyFramingham Risk Scorebusiness.industryIncidence (epidemiology)Percutaneous coronary interventionGeneral MedicineTreatment OutcomeMulticenter studyCohortCardiology and Cardiovascular MedicinebusinessTIMIMace
researchProduct

Prevalence of Vertebral Fractures and Their Prognostic Significance in the Survival in Patients with Chronic Kidney Disease Stages 3‒5 Not on Dialysis

2020

Background: The prevalence of vertebral fractures (VF) and their association with clinical risk factors and outcomes are poorly documented in chronic kidney disease (CKD) cohorts. The aim of the study was to evaluate the prevalence of VF in patients with non-dialysis dependent CKD (NDD-CKD), their value in predicting mortality and its correlation with parameters of bone mineral metabolism and vascular calcification. Materials and Methods: 612 NDD 3‒5 stage CKD patients participating in the OSERCE-2 study, a prospective, multicenter, cohort study, were prospectively evaluated and categorized into two groups according to presence or absence of VF at enrollment. VF were assessed with lateral r…

medicine.medical_specialtymedicine.medical_treatmentOsteoporosis030232 urology & nephrologylcsh:Medicine030209 endocrinology & metabolismLogistic regressionArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineRisk factorSurvival analysisDialysisVascular diseasebusiness.industrylcsh:RGeneral Medicinefracturesmedicine.diseasevascular calcificationbusinesschronic kidney diseaseCohort studyKidney diseaseJournal of Clinical Medicine
researchProduct

Survival with low- and high-flux dialysis

2021

The National Program of I + D + I 2008–2011 and Instituto de Salud Carlos III (ISCIII), the ISCIII Retic REDinREN (RD06/0016/1013, RD12/0021/0023 and RD16/ 0009/0017), the ISCIII (ICI14/00107, PI17/00384 and PI20/00633), Fondo Europeo de Desarrollo Regional (FEDER), Plan Estatal de I + D + I 2013–2016, Plan de Ciencia, Tecnología e Innovación 2013–2017 y 2018–2022 del Principado de Asturias (GRUPIN14-028, IDI-2018-000152) (...)

medicine.medical_specialtymedicine.medical_treatmentPopulation030232 urology & nephrology610030204 cardiovascular system & hematologyPeritoneal dialysis03 medical and health sciences0302 clinical medicineInternal medicinemedicineddc:610AcademicSubjects/MED00340educationDialysisTransplantationeducation.field_of_studychronic haemodialysisbusiness.industryMortality rateHazard ratioOriginal ArticlesmortalityNephrologyRelative riskPropensity score matchingdialysismortality riskHemodialysisbusinessdialysis membranes
researchProduct

Chronic kidney disease and dyslipidaemia

2016

Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and …

medicine.medical_specialtymedicine.medical_treatmentRenal functionDisease030204 cardiovascular system & hematologyurologic and male genital diseases03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumans030212 general & internal medicineRenal replacement therapyRenal Insufficiency ChronicIntensive care medicineDyslipidemiasGeneral Environmental ScienceCardiovascular mortalitybusiness.industryAnticholesteremic AgentsGeneral EngineeringCholesterol LDLmedicine.diseaseRenal Replacement TherapyCardiovascular DiseasesRenal transplantDisease ProgressionPhysical therapyGeneral Earth and Planetary SciencesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessVery high riskDyslipidemiaKidney diseaseClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct